[HTML][HTML] Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017

C Hiemke, N Bergemann, HW Clement… - …, 2018 - thieme-connect.com
Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug
concentrations in blood to optimize pharmacotherapy. It considers the interindividual …

Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction

JP Zhang, AK Malhotra - Expert opinion on drug metabolism & …, 2011 - Taylor & Francis
Importance of the field: Antipsychotic drug is the mainstay of treatment for schizophrenia,
and there are large inter-individual differences in clinical response and side effects …

[HTML][HTML] Theranostic biomarkers for schizophrenia

M Nikolac Perkovic, G Nedic Erjavec… - International journal of …, 2017 - mdpi.com
Schizophrenia is a highly heritable, chronic, severe, disabling neurodevelopmental brain
disorder with a heterogeneous genetic and neurobiological background, which is still poorly …

New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders

G Di Giovanni, P De Deurwaerdère - Pharmacology & therapeutics, 2016 - Elsevier
Abstract The 5-HT 2C receptor (R) displays a widespread distribution in the CNS and is
involved in the action of 5-HT in all brain areas. Knowledge of its functional role in the CNS …

Pharmacogenetics of antipsychotics

EJ Brandl, JL Kennedy… - The Canadian Journal of …, 2014 - journals.sagepub.com
Objective: During the past decades, increasing efforts have been invested in studies to
unravel the influence of genetic factors on antipsychotic (AP) dosage, treatment response …

Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy

CA Altar, J Hornberger, A Shewade… - International review of …, 2013 - Taylor & Francis
Adverse events, response failures and medication non-compliance are common in patients
receiving medications for the treatment of mental illnesses. A systematic literature review …

[HTML][HTML] Putative role of immune reactions in the mechanism of tardive dyskinesia

AJM Loonen - Brain, Behavior, & Immunity-Health, 2023 - Elsevier
The term extrapyramidal disorders is most often used for conditions such as Parkinson's
disease or Huntington's disease, but also refers to a group of extrapyramidal side effects of …

Genetics of tardive dyskinesia: promising leads and ways forward

CC Zai, MS Maes, AK Tiwari, GC Zai… - Journal of the …, 2018 - Elsevier
Tardive dyskinesia (TD) is a potentially irreversible and often debilitating movement disorder
secondary to chronic use of dopamine receptor blocking medications. Genetic factors have …

Поиск биомаркеров и разработка фармакогенетических подходов к персонализированной терапии больных шизофренией

СА Иванова, ОЮ Федоренко, ЛП Смирнова… - … вестник психиатрии и …, 2013 - elibrary.ru
В статье представлены предварительные результаты исследований в области
трансляционной психиатрии. Основные направления связаны с поиском биомаркеров …

Pharmacogenetics of tardive dyskinesia: an updated review of the literature

RK Lanning, CC Zai, DJ Müller - Pharmacogenomics, 2016 - Taylor & Francis
Tardive dyskinesia (TD) is a serious and potentially irreversible side effect of long-term
exposure to antipsychotic medication characterized by involuntary trunk, limb and orofacial …